Vitiligo Treatment When Topical Therapy Has Not Achieved Repigmentation
For patients with vitiligo who did not achieve adequate repigmentation on topical therapy,
a structured next-line protocol guides the escalation step — with defined selection criteria
based on the extent of disease involvement.
Previous Line — Reason for Escalation
First-line topical management — including calcineurin inhibitors (tacrolimus ointment or
pimecrolimus cream), potent topical corticosteroids, and the topical JAK-inhibitor
ruxolitinib cream — was the initial approach. When repigmentation, particularly at the
face and neck, is not achieved by the 3-month assessment point, escalation to the next
treatment line is indicated.
Clinical Goals at This Stage
The primary objectives are to halt disease activity and achieve repigmentation of vitiligo
lesions. Response is assessed over a defined course of treatment sessions; patients who do
not respond within the expected window are considered non-responders.
Next-Line Approach (Partial)
The protocol at this stage centres on a phototherapy-based regimen. The specific modality
is selected based on the extent of skin involvement. Phototherapy is often combined with
topical agents for optimal response. The complete protocol — including modality selection,
parameters, and combination strategy — is available below.
References
DOI: 10.1111/jdv.19450
NB-UVB is the preferred first-line therapy for widespread or rapidly progressive disease.
NB-UVB is the modality of choice to administer total body UV treatment, while excimer lamp or laser 308 nm UV sources are preferred for limited vitiligo.
Early initiation of NB-UVB is encouraged, because of its ability to halt disease activity and induce repigmentation.
Consider non-responders after 30-48 sessions; some late responders may require 72 sessions.
For optimal repigmentation, the combination of TCI with UV light can be considered, taking safety aspects into account.
View source ↗